Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 35

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 35
---
, or other similar agreements with us prior to beginning research or disclosing proprietary information. These agreements typically
limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current
or former employees, consultants, collaborators, contractors, and advisors may unintentionally or willfully disclose our confidential
information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure
of confidential information. The need to share trade secrets and other confidential information increases the risk that such trade secrets
become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation
of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery
of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on
our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential
know-how is expensive, time consuming, and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction
to jurisdiction. 

In
addition, these agreements typically restrict the ability of our employees, consultants, collaborators, contractors, and advisors to
publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite
our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with
third parties, independent development, or publication of information by any of our third-party collaborators. A competitor’s discovery
of our trade secrets would impair our competitive position and have an adverse impact on our business. 

We
may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed to us alleged
trade secrets of their former employers or their former or current customers.

As
is common in the biotechnology and pharmaceutical industries, certain of our employees were formerly employed by other biotechnology
or pharmaceutical companies, including our competitors or potential competitors. Moreover, we engage the services of consultants to assist
it in the development of our products and clinical assets, many of whom were previously employed at or may have previously been or are
currently providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors.
We may be subject to claims that these employees and consultants or we have inadvertently or otherwise used or disclosed trade secrets
or other proprietary information of their former employers or their